Description: Iconovo AB (publ) develops and licenses inhalation devices in Sweden. It develops ICOres, a flexible multi-dose dry powder inhaler; ICOcap, a capsule based dry powder inhaler; ICOone, a single-dose disposable dry powder inhaler; and ICOpre, a pre-metered dry powder inhaler; ICOone single-dose disposable dry powder inhaler; and ICOone nasal single-dose dry powder inhaler now for nasal use. It serves generic companies. The company has an agreement with Immune System Regulation AB for the development of an inhaled covid-19 vaccine in Iconovo's inhaler ICOone; and Respiratorius to develop dry powder inhalation product. Iconovo AB (publ) was founded in 2013 and is based in Lund, Sweden.
Home Page: www.iconovo.se
Medicon Village
Lund,
223 81
Sweden
Phone:
46 4 62 75 67 77
Officers
| Name | Title |
|---|---|
| Mr. Johan Waborg | Chief Exec. Officer |
| Dr. Orest Lastow | CTO, Co-Founder & Director |
| Peter Akerlund | Chief Financial Officer |
| Dr. Mikael Arinder | VP of Operations |
| Eva Norell | Communications & Marketing Mang. |
| Mr. Carl Forslund | Head of Industrial Design |
Exchange: ST
Country: SE : Sweden
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 4.247 |
| Price-to-Sales TTM: | 13.3553 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 31 |